We developed novel nanoprobes targeting a HER2 expression gastric cancer PDX model with micro-PET/CT and PET/MRI imaging to improve the retention time of monoclonal antibodies in tumor sites, reduce cardiac toxicity, and monitor the therapeutic effect in real time through multimodal imaging. This evidence concerns the gene ERBB2 and gastric cancer.